This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Voet D, Voet JG. Biochemistry (3rd ed.). Hoboken, New Jersey, 2004; USA: John Wiley & Sons Inc.Search in Google Scholar
Kang E, Kim Y, Kang M, Heo S, Kim G, Choi I, et al. Clinical and genetic characteristics of patients with fatty acid oxidation disorders identified by newborn screening. BMC Pediatr 2018;18(1):103.Search in Google Scholar
Merritt JL, Norris M, Kanungo S. Fatty acid oxidation disorders. Ann Transl Med 2018;6(24):473.Search in Google Scholar
La Marca G. Mass spectrometry in clinical chemistry: the case of newborn screening. J Pharm Biomed Anal 2014;101:174-82.Search in Google Scholar
Ozben T. Expanded newborn screening and confirmatory follow-up testing for inborn errors of metabolism detected by tandem mass spectrometry. Clinic Chem Lab Med 2013;51(1):157-76.Search in Google Scholar
Recommended Uniform Screening Panel. https://www.hrsa.gov/advisorycommittees/heritable-disorders/rusp/index.html. (accessed 20 July 2020).Search in Google Scholar
McHugh DMS, Cameron CA, Abdenur JE, Abdulrahman M, Adair O, Nuaimi SAA, et al. Clinical validation of cutoff target ranges in newborn screening of metabolic disorders by tandem mass spectrometry: a worldwide collaborative project. Genet Med 2011;13(3):230-54.Search in Google Scholar
CLSI (2017). Newborn Screening by Tandem Mass Spectrometry. CLSI guideline: NBS 04. (2nd ed.). Wayne, PA, USA: Clinical and Laboratory Standards Institute.Search in Google Scholar
Therrell BL, Padilla CD, Loeber JG, Kneisser I, Saadallah A, Borrajo GJC, Adams J. Current status of newborn screening worldwide: 2015. Semin Perinatol 2015;39(3):171-87.Search in Google Scholar
CLSI (2013). Blood Collection on Filter Paper for Newborn Screening Programs. CLSI document: NBS01-A6. (6th ed.). Wayne, PA, USA: Clinical and Laboratory Standards Institute.Search in Google Scholar
Demirelce Ö, Aksungar FB, Saral NY, Kilercik M, Serteser M, Unsal I. Institutional experience of newborn screening for inborn metabolism disorders by tandem MS in the Turkish population. J Pediatr Endocrinol Metab 2020;33(6):703-11.Search in Google Scholar
Vilarinho L, Rocha H, Sousa C, Marcão A, Fonseca H, Bogas M, Osório RV. Four years of expanded newborn screening in Portugal with tandem mass spectrometry. J Inherit Metab Dis 2010;33(S3):S133-8.Search in Google Scholar
David J, Chrastina P, Pesková K, Kozich V, Friedecký D, Adam T, et al. Epidemiology of rare diseases detected by newborn screening in the Czech Republic. Cent Eur J Public Health 2019;27(2):153-9.Search in Google Scholar
Smon A, Groselj U, Debeljak M, Zerjav Tansek M, Bertok S, Avbelj Stefanija M, et al. Medium-chain acyl-CoA dehydrogenase deficiency: Two novel ACADM mutations identified in a retrospective screening. J Int Med Res 2018;46(4):1339-48.Search in Google Scholar
El-Gharbawy A, Vockley J. Inborn errors of metabolism with myopathy: Defects of fatty acid oxidation and the carnitine shuttle system. Pediatr Clin North Am 2018;65(2):317-35.Search in Google Scholar
Groselj U, Zerjav Tansek M, Smon A, Angelkova N, Anton D, Baric I, et al. Newborn screening in southeastern Europe. Mol Genet Metab 2014;113(1-2):42-5.Search in Google Scholar
